Teva Pharmaceutical Industries Ltd. $TEVA Shares Bought by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. raised its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 13.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 32,582,212 shares of the company’s stock after acquiring an additional 3,896,790 shares during the quarter. Teva Pharmaceutical Industries makes up approximately 7.1% of Migdal Insurance & Financial Holdings Ltd.’s investment portfolio, making the stock its largest position. Migdal Insurance & Financial Holdings Ltd.’s holdings in Teva Pharmaceutical Industries were worth $658,161,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Cromwell Holdings LLC lifted its position in shares of Teva Pharmaceutical Industries by 40.3% during the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in Teva Pharmaceutical Industries during the second quarter worth $41,000. Sound Income Strategies LLC raised its position in Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after acquiring an additional 2,824 shares during the period. JTC Employer Solutions Trustee Ltd purchased a new position in Teva Pharmaceutical Industries during the third quarter valued at $65,000. Finally, MAI Capital Management grew its position in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after purchasing an additional 697 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 216,892 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total value of $6,231,307.16. Following the transaction, the insider directly owned 52,828 shares in the company, valued at approximately $1,517,748.44. This represents a 80.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Roberto Mignone sold 77,400 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the sale, the director owned 367,600 shares of the company’s stock, valued at $11,116,224. This trade represents a 17.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 622,060 shares of company stock valued at $17,076,965 in the last quarter. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $31.38 on Wednesday. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $33.42. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The stock has a market cap of $35.99 billion, a price-to-earnings ratio of 52.30, a price-to-earnings-growth ratio of 1.82 and a beta of 0.66. The business has a fifty day moving average of $29.27 and a two-hundred day moving average of $22.35.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several research reports. Scotiabank assumed coverage on Teva Pharmaceutical Industries in a research report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 price target for the company. Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Barclays initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price target on the stock. Finally, UBS Group upped their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $33.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.